1710-62-9

Usage

Uses

Used in Pharmaceutical Industry:
5-(2-Bromoethoxy)-2,3-dihydro-1,4-benzodioxine is utilized as a building block for the synthesis of biologically active compounds. Its structural features make it a valuable component in the development of new pharmaceuticals, contributing to the creation of diverse medicinal agents.
Used in Drug Development:
As a potential drug candidate, 5-(2-Bromoethoxy)-2,3-dihydro-1,4-benzodioxine has been studied for its possible applications in medicine. Its unique structure and properties may offer therapeutic benefits in various medical conditions, although further research is necessary to fully understand its potential and efficacy.

InChI:InChI=1/C10H11BrO3/c11-4-5-12-8-2-1-3-9-10(8)14-7-6-13-9/h1-3H,4-7H2

Upstream product

• 10288-36-5 2,3-dihydro-1,4-benzodioxin-5-ol 
• 106-93-4 ethylene dibromide 

Downstream Products

• 1459261-59-6 2-(2,3-dihydro-1,4-benzodioxin-5-yloxy)-N-metyl-N-(3-nitrobenzyl)ethylamine 
• 32604-73-2 2-(2,3-dihydrobenzo[1,4]dioxin-5-yloxy)-ethylamine 

Relevant academic research and scientific papers

Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT1AReceptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile

Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives with high affinity and selectivity for serotonin 5-HT1A receptors were obtained and tested in four functional assays: ERK1/2 phosphorylation, adenylyl cyclase inhibition, calcium mobilization, and β-arrestin recruitment. Compounds 44 and 56 (2-methylaminophenoxyethyl and 2-(1H-indol-4-yloxy)ethyl derivatives, respectively) were selected as biased agonists with highly differential "signaling fingerprints"that translated into distinct in vivo profiles. In vitro, 44 showed biased agonism for ERK1/2 phosphorylation and, in vivo, it preferentially exerted an antidepressant-like effect in the Porsolt forced swimming test in rats. In contrast, compound 56 exhibited a first-in-class profile: it preferentially and potently activated β-arrestin recruitment in vitro and potently elicited lower lip retraction in vivo, a component of "serotonergic syndrome". Both compounds showed promising developability properties. The presented 5-HT1A receptor-biased agonists, preferentially targeting various signaling pathways, have the potential to become drug candidates for distinct central nervous system pathologies and possessing accentuated therapeutic activity and reduced side effects.

Substituted oxygenated heterocycles and thio-analogues: Synthesis and biological evaluation as melatonin ligands

A new series of substituted oxygenated heterocycles and thio-analogues were synthesized and evaluated as melatonin receptor ligands. The replacement of the indolic moiety of melatonin by heterocyclic skeleton such as 1,4- benzodioxin, 2,3-dihydro-1,4-benzodioxin, chroman, 2,3-dihydro-1,4- benzoxathiin, thiochroman, carrying the amidic chain on the aromatic ring, leads to compounds showing a weak affinity for melatonin receptors, except for the compounds 1cb and 1hb. (C) 2000 Elsevier Science Ltd.

Heterocyclic compounds

The invention relates to compound of general formula (I): STR1 wherein: Z represents O or CH 2n is from 0 to 4R, X and Y are as defined in the description, andA represents STR2 wherein R 1, R 2, R 6, R 7 and T'' are as defined in the description,and medicinal products containing the same are useful in treating or in preventing melatoninergic disorders.